Elevated FIB-4 Is Associated with Higher Rates of Cardiovascular Disease and Extrahepatic Cancer History in Patients with Type 2 Diabetes Mellitus

Dimitrios S. Karagiannakis,Katerina Stefanaki,Foteini Petrea,Panagiota Zacharaki,Alexandra Giannou,Olympia Michalopoulou,Paraskevi Kazakou,Theodora Psaltopoulou,Vasiliki Vasileiou,Stavroula A. Paschou
DOI: https://doi.org/10.3390/biomedicines12040823
IF: 4.757
2024-04-09
Biomedicines
Abstract:Background: Type 2 diabetes mellitus (T2DM) is often complicated by steatotic liver disease, cardiovascular disease (CVD), and extrahepatic cancer. We investigated whether FIB-4, an indicator of liver fibrosis, is associated with a higher risk of CVD and extrahepatic cancer history in T2DM. Methods: Two hundred and nine of 244 diabetics admitted to our center in one year were included and retrospectively evaluated. Results: One hundred and fifty-two (72.7%) were males and 57 (27.3%) females. The mean age and FIB-4 were 64.3 ± 11 years, and 1.15 ± 0.5, respectively. One hundred and fifty patients (71.8%) had FIB-4 ≤ 1.3, and 59 (28.2%) had FIB-4 > 1.3. A history of CVD was presented in 76 (36.4%) patients, and of extrahepatic cancer in 39 (18.7%). Patients with CVD were significantly older than those without (68.4 ± 8.5 vs. 63.2 ± 11.5 years; p = 0.002), with significantly higher FIB-4 (1.26 ± 0.5 vs. 1.08 ± 0.5; p = 0.012). Patients with cancer were older, with higher FIB-4 compared to those without (68.2 ± 9.5 vs. 64.4 ± 10.9 years; p = 0.098 and 1.37 ± 0.6 vs. 1.1 ± 0.5; p = 0.004, respectively). FIB-4 > 1.3 was associated with a 2.1-fold probability for CVD (χ2 = 5.810; p = 0.025) and 2.7-fold probability for cancer history (χ2 = 7.603; p = 0.01). Conclusions: FIB-4 ≥ 1.3 is associated with a higher probability of CVD or extrahepatic cancer history. FIB-4 could potentially discriminate patients at risk, justifying stricter surveillance.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore whether FIB - 4 (Fibrosis - 4 Index) is associated with an increased historical risk of cardiovascular disease (CVD) and extra - hepatic cancers in patients with type 2 diabetes. Specifically, the researchers hope to evaluate whether FIB - 4 levels can be used as a predictor of the history of cardiovascular disease and extra - hepatic cancers in patients with type 2 diabetes, especially the application effect in different age groups. In addition, the study also explored the feasibility of using the two thresholds of 1.3 and 2 for FIB - 4 to distinguish high - risk individuals among patients with type 2 diabetes. ### Research Background Type 2 diabetes mellitus (T2DM) is a serious metabolic disease, often accompanied by multiple complications, such as chronic kidney disease (CKD), cardiovascular disease (CVD) and cancer. In addition, T2DM is often accompanied by metabolic - dysfunction - associated steatotic liver disease (MASLD), a liver disease related to metabolic syndrome, and its incidence is rising globally. The severity of MASLD ranges from simple fatty liver to severe fibrosis and cirrhosis. Liver fibrosis is not only associated with an increased risk of liver - related diseases, but also with an increased risk of cardiovascular disease and extra - hepatic cancers. ### Research Objectives 1. **Evaluate the relationship between FIB - 4 and the history of cardiovascular disease and extra - hepatic cancers in patients with type 2 diabetes**: - Explore whether FIB - 4 levels can be used as a predictor of the history of cardiovascular disease and extra - hepatic cancers in patients with type 2 diabetes. - Evaluate whether patients with FIB - 4 > 1.3 have a higher historical risk of cardiovascular disease and extra - hepatic cancers. 2. **Evaluate the application effect of FIB - 4 in different age groups**: - Pay special attention to the application of FIB - 4 in patients over 65 years old, and explore whether FIB - 4 ≥ 2 can more accurately identify high - risk individuals. ### Research Methods - **Patient selection**: 209 patients with type 2 diabetes were included, and diseases or factors that may affect liver fibrosis were excluded. - **Data collection**: Record the epidemiological characteristics, biochemical indicators, and history of clinical events of patients. - **Statistical analysis**: Use SPSS software for statistical analysis, compare the differences between different groups, and perform multivariate regression analysis to determine independent risk factors. ### Main Findings - **FIB - 4 and cardiovascular disease**: - The risk of cardiovascular disease in patients with FIB - 4 > 1.3 is 2.1 times that of patients with FIB - 4 ≤ 1.3 (χ² = 5.810, p = 0.025). - Multivariate analysis shows that gender (male), history of hypertension and duration of diabetes are independent risk factors for cardiovascular disease. - **FIB - 4 and extra - hepatic cancers**: - The risk of extra - hepatic cancers in patients with FIB - 4 > 1.3 is 2.7 times that of patients with FIB - 4 ≤ 1.3 (χ² = 7.603, p = 0.01). - Univariate analysis shows that FIB - 4 > 1.3 and age are significantly associated with the history of extra - hepatic cancers. - **Patients over 65 years old**: - In patients over 65 years old, FIB - 4 ≥ 2 has no significant correlation with the history of cardiovascular disease and extra - hepatic cancers. ### Conclusion FIB - 4 ≥ 1.3 is associated with an increased historical risk of cardiovascular disease and extra - hepatic cancers in patients with type 2 diabetes and can be used as a potential predictor for these patients. However, for patients over 65 years old, FIB - 4 ≥ 2 may not be the best predictor. These findings help clinicians better identify and manage high - risk individuals among patients with type 2 diabetes, so as to take more stringent monitoring measures.